A subcarinal lymph-node biopsy showed noncaseating granulomas with no evidence of necrosis. There were multinucleated giant cells within granulomas, and peripherally the granulomas were surrounded by lymphocytes. The biopsy was negative for fungal and mycobacterial organisms, with negative AFB and PAS stains. Thus, pathology was not diagnostic of lymphoma. However, there was still a clinical suspicion for lymphoma given the lack of any significant pulmonary findings or extrapulmonary findings that would be consistent with sarcoidosis. Angiotensinconverting enzyme concentrations were within the normal range. A CT-guided bone-marrow aspiration and biopsy was done again, showing noncaseating granulomas with cytogenics indicating no evidence of B-cell or T-cell lymphoma. A peripheral smear revealed normal red-and white-cell maturation with adequate platelets.
With no pathology diagnostic of lymphoma, we started treatment for possible atypical sarcoidosis. The patient was started on hydroxychloroquine 200 mg by mouth twice a day and a prednisone taper starting at 20 mg by mouth twice a day. One month after starting treatment for sarcoidosis, the patient reported almost complete resolution of her symptoms, including resolution of fevers, chills, night sweats, and weight loss and had tapered her prednisone to 10 mg daily. A repeat PET scan showed a decrease in the activity levels of hypermetabolic lymph nodes throughout the mediastinum and bilateral pulmonary hilar regions. The largest nodal mass within the subcarinal mediastinum regressed in size and activity from an SUV of 44.7 to 14.2. Hypermetabolic lymph nodes within the pulmonary hila regressed in activity; on the right, SUV decreased from 30.9 to 12.1, and on the left, SUV decreased from 24.0 to 10.4. These findings suggest a positive therapeutic response (Fig. 3 ). This is an atypical presentation for sarcoidosis. However, the pathology findings, a positive response to treatment, and improvement on PET scan make a convincing case that our patient has underlying sarcoidosis.
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Sarcoidosis is a systemic, chronic, granulomatous disorder. Although the cause is unknown, the immune system clearly plays a central role in pathogenesis (3). The sarcoid granuloma contains a central follicle of tightly packed epitheloid cells and multinucleated giant cells surrounded by lymphocytes, macrophages, monocytes, and fibroblasts. The initial inflammation is mainly composed of activated CD4 T helper cells whose cytokines recruit other cells to help form the granulomas (4).
Respiratory symptoms are the most common presenting complaints and include dry cough, dyspnea, and nonspecific chest pain-none of which our patient had. Fever, weight loss, fatigue, and malaise are the presenting symptoms in 25% of patients (5) . At presentation, 95% of patients have clinical evidence of pumonary sarcoidosis, and more than 40% of sarcoidosis patients have evidence of involvement of the skin, peripheral lymph node, eye, or liver (6) .
Radiographic findings alone are inadequate to make a diagnosis of sarcoidosis. Likewise, the presence of noncaseating granulomas on biopsy is not definitive (7) . It is essential to rule out other causes of noncaseating granulomas first. Thus, every biopsy should be searched for other causes of noncaseating granulomas including malignancy, mycobacteria, fungi, parasites, other infections, and foreign bodies (8) .
PET, a molecular functional imaging technique, has become the most important nuclear medicine imaging modality in the field of lymphoma. It is able to detect occult disease missed by conventional imaging techniques (9) . This case clearly illustrates that not every PET-positive lesion represents malignancy, and a tissue biopsy is mandatory to confirm the diagnosis.
Inflammatory cells such as neutrophils, activated macrophages, and lymphocytes have increased 18F-FDG uptake, causing important tracer accumulation in inflammatory and infectious processes (10) . Thus, false-positive findings with an SUV higher than 2.5 (which is suggestive of malignancy) have been reported in inflammatory and granulomatous diseases, such as aspergillosis, tuberculosis, Wegener's granulomatosis, and sarcoidosis (11). In one case series, five patients with mediastinal lymph node enlargement suggestive of lymphoma, lung cancer, or sarcodoisis were studied with 18F-FDG PET/CT. This study illustrated that sarcoidosis can be a pitfall in PET/CT imaging, and may lead to false-positive results of malignancy (12) . Another study of 20 cases demonstrated the 18F-FDG PET sensitivity for sarcoid lesions in several areas: thoracic (100%), sinonasal (100%), and pharyngolaryngeal (80%). A high standardized uptake value on PET could be misconstrued as indicative of malignancy, and clinical factors, patterns of FDG uptake, and newer PET radiotracers such as 18-fluoro-methyltyrosine (18F-FMT) may aid in distinguishing this benign disease from malignant tumor (13) .
A study group of 24 sarcoid patients with suspected malignancy underwent both 18F-FDG and 18F-FMT PET (14) . All patients showed increased uptake of 18F-FDG and no increase in the accumulation of 18F-FMT in their lymphadenopathy. No neoplasm was confirmed in any patient. Since the uptake of 18F-FDG was positive in these sarcoid lesions, 18F-FDG PET could not differentiate sarcoidosis from malignant disease. This suggests that use of 18F-FMT PET in combination with 18F-FDG PET may be an effective method to distinguish sarcoidosis from malignancy.
Our case shows that PET scans can aid in the diagnosis of sarcoidosis and might also be used to monitor therapeutic response. Further research needs to be performed regarding the usefulness of 18F-FDG PET, as well as the use of newer radiotracers such as 18F-FMT, for the diagnosis and followup of sarcoid patients as well as for differentiating sarcoid from malignant lymphoma (10) .
